Anti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source)

N/A

Report date: 2026/03/19 16:47:04

Base Information

Drug NameAnti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source)

Drug Alias Name抗CD3-抗-CD19双特异性单克隆抗体Monoclonal antibody SHR-1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsT cell surface glycoprotein CD3 inhibitors

TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive Companies +[1] N/A

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A